Compare Stocks

Date Range: 

 Akebia TherapeuticsVerastemFortress BiotechForte Biosciences89bio
SymbolNASDAQ:AKBANASDAQ:VSTMNASDAQ:FBIONASDAQ:FBRXNASDAQ:ETNB
Price Information
Current Price$3.05$2.96$4.06$34.48$23.99
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.81.11.61.71.6
Analysis Score3.31.54.53.53.6
Community Score2.72.62.73.52.9
Dividend Score0.00.00.00.00.0
Ownership Score1.70.80.00.81.7
Earnings & Valuation Score1.30.60.60.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$9.63$3.00$10.80$82.00$61.88
% Upside from Price Target215.57% upside1.35% upside166.01% upside137.82% upside157.92% upside
Trade Information
Market Cap$487.72 million$503.84 million$394.85 million$467.82 million$499.47 million
Beta2.110.722.430.23N/A
Average Volume5,738,8872,717,9861,601,775176,126140,491
Sales & Book Value
Annual Revenue$335 million$17.46 million$36.63 million$40,000.00N/A
Price / Sales1.4629.1010.7811,644.76N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$3.32 per share$0.09 per share$1.02 per share$6.81 per share$6.92 per share
Price / Book0.9232.893.985.06N/A
Profitability
Net Income$-279,660,000.00$-149,210,000.00$-39,960,000.00$-63,520,000.00$-57,420,000.00
EPS($1.63)($2.00)($0.73)($40.33)($24.49)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-126.86%-590.19%-131.98%N/AN/A
Return on Equity (ROE)-68.51%-189.37%-44.08%-417.87%-49.56%
Return on Assets (ROA)-34.01%-67.69%-19.06%-248.28%-46.52%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.24%0.45%0.29%N/AN/A
Current Ratio2.15%5.02%6.38%8.97%23.61%
Quick Ratio1.67%4.80%6.35%8.97%23.61%
Ownership Information
Institutional Ownership Percentage68.98%42.15%32.13%53.03%80.63%
Insider Ownership Percentage2.55%2.90%29.50%10.90%18.10%
Miscellaneous
Employees37948111926
Shares Outstanding159.91 million171.67 million97.25 million13.51 million20.04 million
Next Earnings Date5/10/2021 (Confirmed)5/6/2021 (Estimated)5/10/2021 (Estimated)5/10/2021 (Confirmed)5/12/2021 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableNot Optionable
SourceHeadline
89bio to Present at Upcoming Investor Conferences - GlobeNewswire89bio to Present at Upcoming Investor Conferences - GlobeNewswire
globenewswire.com - May 5 at 8:28 AM
89bio, Inc. (NASDAQ:ETNB) Short Interest Up 20.5% in April89bio, Inc. (NASDAQ:ETNB) Short Interest Up 20.5% in April
americanbankingnews.com - May 4 at 4:44 PM
89bio (NASDAQ:ETNB) Stock Price Up 4.3%89bio (NASDAQ:ETNB) Stock Price Up 4.3%
americanbankingnews.com - April 27 at 12:54 PM
89bio (NASDAQ:ETNB) Earns Overweight Rating from Analysts at Cantor Fitzgerald89bio (NASDAQ:ETNB) Earns Overweight Rating from Analysts at Cantor Fitzgerald
americanbankingnews.com - April 27 at 9:12 AM
Insider Selling: 89bio, Inc. (NASDAQ:ETNB) Director Sells 850 Shares of StockInsider Selling: 89bio, Inc. (NASDAQ:ETNB) Director Sells 850 Shares of Stock
americanbankingnews.com - April 23 at 11:04 PM
Brokers Offer Predictions for 89bio, Inc.s FY2021 Earnings (NASDAQ:ETNB)Brokers Offer Predictions for 89bio, Inc.'s FY2021 Earnings (NASDAQ:ETNB)
americanbankingnews.com - April 23 at 8:22 AM
89bio (NASDAQ:ETNB)  Shares Down 6.3% 89bio (NASDAQ:ETNB) Shares Down 6.3%
americanbankingnews.com - April 22 at 1:36 PM
Benzingas Top Ratings Upgrades, Downgrades For April 21, 2021 - BenzingaBenzinga's Top Ratings Upgrades, Downgrades For April 21, 2021 - Benzinga
benzinga.com - April 21 at 1:52 PM
Is it Time to Dump 89bio Inc (ETNB) Stock After it Is Up 15.35% in a Week? - InvestorsObserverIs it Time to Dump 89bio Inc (ETNB) Stock After it Is Up 15.35% in a Week? - InvestorsObserver
investorsobserver.com - April 21 at 1:52 PM
89bio could close the valuation gap with Akero by end of 2021: Cantor - Seeking Alpha89bio could close the valuation gap with Akero by end of 2021: Cantor - Seeking Alpha
seekingalpha.com - April 21 at 1:52 PM
89bio (NASDAQ:ETNB) Shares Gap Up to $25.8189bio (NASDAQ:ETNB) Shares Gap Up to $25.81
americanbankingnews.com - April 21 at 10:36 AM
Cantor Fitzgerald Begins Coverage on 89bio (NASDAQ:ETNB)Cantor Fitzgerald Begins Coverage on 89bio (NASDAQ:ETNB)
americanbankingnews.com - April 21 at 8:28 AM
Ryan Martins Sells 10,000 Shares of 89bio, Inc. (NASDAQ:ETNB) StockRyan Martins Sells 10,000 Shares of 89bio, Inc. (NASDAQ:ETNB) Stock
americanbankingnews.com - April 20 at 7:42 PM
89bio (NASDAQ:ETNB) Stock Price Up 3%89bio (NASDAQ:ETNB) Stock Price Up 3%
americanbankingnews.com - April 20 at 1:58 PM
89bio, Inc. (NASDAQ:ETNB) Insider Ram Waisbourd Sells 7,000 Shares89bio, Inc. (NASDAQ:ETNB) Insider Ram Waisbourd Sells 7,000 Shares
americanbankingnews.com - April 19 at 7:46 PM
89bio (NASDAQ:ETNB) Is In A Good Position To Deliver On Growth Plans - Nasdaq89bio (NASDAQ:ETNB) Is In A Good Position To Deliver On Growth Plans - Nasdaq
nasdaq.com - April 15 at 5:11 PM
89bio, Inc. (NASDAQ:ETNB) Given Average Recommendation of "Buy" by Analysts89bio, Inc. (NASDAQ:ETNB) Given Average Recommendation of "Buy" by Analysts
americanbankingnews.com - April 15 at 5:04 PM
Health Archives - Market PrimesHealth Archives - Market Primes
marketprimes.com - April 14 at 7:58 AM
Clinical Catch-Up: April 5-9 - BioSpaceClinical Catch-Up: April 5-9 - BioSpace
biospace.com - April 13 at 12:38 AM
Leerink Partners Sticks to Their Buy Rating for 89bio (ETNB) - Smarter AnalystLeerink Partners Sticks to Their Buy Rating for 89bio (ETNB) - Smarter Analyst
smarteranalyst.com - April 9 at 12:19 PM
89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH - Yahoo Finance89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH - Yahoo Finance
finance.yahoo.com - April 6 at 7:50 PM
Do Traders Think 89bio Inc (ETNB) Can Keep Climbing Monday? - InvestorsObserverDo Traders Think 89bio Inc (ETNB) Can Keep Climbing Monday? - InvestorsObserver
investorsobserver.com - April 5 at 11:01 PM
89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH - GlobeNewswire89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH - GlobeNewswire
globenewswire.com - April 5 at 1:00 PM
89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH
finance.yahoo.com - April 5 at 1:00 PM
Implied VHT Analyst Target Price: $260 - NasdaqImplied VHT Analyst Target Price: $260 - Nasdaq
nasdaq.com - April 1 at 2:25 PM
DateCompanyBrokerageAction
3/15/2021Akebia TherapeuticsHC WainwrightLower Price Target
3/15/2021Akebia TherapeuticsCantor FitzgeraldInitiated Coverage
1/29/2021Akebia TherapeuticsJPMorgan Chase & Co.Downgrade
9/4/2020Akebia TherapeuticsMorgan StanleyLower Price Target
9/4/2020Akebia TherapeuticsBTIG ResearchLower Price Target
9/4/2020Akebia TherapeuticsMizuhoLower Price Target
8/11/2020Akebia TherapeuticsNeedham & Company LLCInitiated Coverage
5/6/2020Akebia TherapeuticsRoyal Bank of CanadaBoost Price Target
8/2/2019VerastemB. RileySet Price Target
5/14/2019VerastemRoth CapitalLower Price Target
5/10/2019VerastemRaymond JamesDowngrade
7/27/2018VerastemSeaport Global SecuritiesSet Price Target
2/17/2021Fortress BiotechDawson JamesBoost Price Target
10/2/2020Fortress BiotechBenchmarkInitiated Coverage
5/21/2018Fortress BiotechJMP SecuritiesSet Price Target
4/1/2021Forte BiosciencesCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
3/26/2021Forte Biosciences(FBRC)Initiated Coverage
3/23/2021Forte BiosciencesChardan CapitalLower Price Target
8/28/2020Forte BiosciencesBrookline Capital ManagementInitiated Coverage
8/25/2020Forte BiosciencesTruist SecuritiInitiated Coverage
6/22/2020Forte BiosciencesLADENBURG THALM/SH SHInitiated Coverage
3/29/202189bioSVB LeerinkBoost Price Target
3/18/202189bioOppenheimerReiterated Rating
9/25/202089bioBank of AmericaUpgrade
7/30/202089bioPiper SandlerInitiated Coverage
(Data available from 5/5/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.